Trial Outcomes & Findings for Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (NCT NCT01898793)
NCT ID: NCT01898793
Last Updated: 2024-01-17
Results Overview
Defined as the dose level immediately below the dose level at which 2 patients of a cohort (of 2 to 6 patients) experience dose-limiting toxicity (DLT) or the maximum dose if less than or equal to 1 patient suffers a DLT at the maximum dose.
Recruitment status
TERMINATED
Study phase
PHASE1/PHASE2
Target enrollment
89 participants
Primary outcome timeframe
35 days
Results posted on
2024-01-17
Participant Flow
* 2 patients enrolled in the Phase I portion of the trial relapsed and were re-enrolled as compassionate use patients and are only included in the enrollment numbers once. * With amendment 16, the decision was made to return to the use of rhIL-2 support instead of ALT-803.
Participant milestones
| Measure |
Phase I Dose Level 1: 0.5 x 10^6/kg CIML NK Cells
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Phase I Dose Level 2: 1.0 x 10^6/kg CIML NK Cells
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Phase I Dose Level 3: 1.0 x 10^7/kg CIML NK Cells
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Lead-in Cohort & Phase II (ALT-803): 1.0 x 10^7/kg CIML NK Cells
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0.
* Subcutaneous ALT-803 will begin approximately 4 hours after the infusion and will continue for a total of 2 doses (Days 0 and 5).
|
Phase II (IL-2): 1.0 x 10^7/kg CIML NK Cells
The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
|
Pediatric Cohort: 1.0 x 10^7/kg CIML NK Cells
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0
* Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses
|
Donors
-The haploidentical donor identified by HLA matching of the immediate family members (parents, siblings, and children) will undergo non-mobilized leukapheresis on Day -1. Peripheral blood mononuclear cells (PBMCs) will be collected using standard collection techniques.
|
|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
5
|
5
|
9
|
8
|
9
|
8
|
45
|
|
Overall Study
COMPLETED
|
3
|
4
|
5
|
8
|
9
|
8
|
45
|
|
Overall Study
NOT COMPLETED
|
2
|
1
|
4
|
0
|
0
|
0
|
0
|
Reasons for withdrawal
| Measure |
Phase I Dose Level 1: 0.5 x 10^6/kg CIML NK Cells
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Phase I Dose Level 2: 1.0 x 10^6/kg CIML NK Cells
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Phase I Dose Level 3: 1.0 x 10^7/kg CIML NK Cells
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Lead-in Cohort & Phase II (ALT-803): 1.0 x 10^7/kg CIML NK Cells
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0.
* Subcutaneous ALT-803 will begin approximately 4 hours after the infusion and will continue for a total of 2 doses (Days 0 and 5).
|
Phase II (IL-2): 1.0 x 10^7/kg CIML NK Cells
The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
|
Pediatric Cohort: 1.0 x 10^7/kg CIML NK Cells
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0
* Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses
|
Donors
-The haploidentical donor identified by HLA matching of the immediate family members (parents, siblings, and children) will undergo non-mobilized leukapheresis on Day -1. Peripheral blood mononuclear cells (PBMCs) will be collected using standard collection techniques.
|
|---|---|---|---|---|---|---|---|
|
Overall Study
Death
|
2
|
1
|
4
|
0
|
0
|
0
|
0
|
Baseline Characteristics
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Baseline characteristics by cohort
| Measure |
Phase I Dose Level 1: 0.5 x 10^6/kg CIML NK Cells
n=5 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Phase I Dose Level 2: 1.0 x 10^6/kg CIML NK Cells
n=5 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Phase I Dose Level 3: 1.0 x 10^7/kg CIML NK Cells
n=9 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Lead-in Cohort & Phase II (ALT-803): 1.0 x 10^7/kg CIML NK Cells
n=8 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0.
* Subcutaneous ALT-803 will begin approximately 4 hours after the infusion and will continue for a total of 2 doses (Days 0 and 5).
|
Phase II (IL-2): 1.0 x 10^7/kg CIML NK Cells
n=9 Participants
The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
|
Pediatric Cohort: 1.0 x 10^7/kg CIML NK Cells
n=8 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0
* Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses
|
Donors
n=45 Participants
-The haploidentical donor identified by HLA matching of the immediate family members (parents, siblings, and children) will undergo non-mobilized leukapheresis on Day -1. Peripheral blood mononuclear cells (PBMCs) will be collected using standard collection techniques.
|
Total
n=89 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
76 years
n=5 Participants
|
72 years
n=7 Participants
|
71 years
n=5 Participants
|
62.5 years
n=4 Participants
|
71 years
n=21 Participants
|
13 years
n=8 Participants
|
46 years
n=8 Participants
|
52 years
n=24 Participants
|
|
Sex: Female, Male
Female
|
1 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
3 Participants
n=21 Participants
|
3 Participants
n=8 Participants
|
22 Participants
n=8 Participants
|
38 Participants
n=24 Participants
|
|
Sex: Female, Male
Male
|
4 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
7 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
6 Participants
n=21 Participants
|
5 Participants
n=8 Participants
|
23 Participants
n=8 Participants
|
51 Participants
n=24 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
4 Participants
n=24 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
5 Participants
n=5 Participants
|
5 Participants
n=7 Participants
|
8 Participants
n=5 Participants
|
8 Participants
n=4 Participants
|
9 Participants
n=21 Participants
|
7 Participants
n=8 Participants
|
38 Participants
n=8 Participants
|
80 Participants
n=24 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
5 Participants
n=24 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
4 Participants
n=8 Participants
|
7 Participants
n=24 Participants
|
|
Race (NIH/OMB)
White
|
3 Participants
n=5 Participants
|
5 Participants
n=7 Participants
|
8 Participants
n=5 Participants
|
7 Participants
n=4 Participants
|
8 Participants
n=21 Participants
|
7 Participants
n=8 Participants
|
36 Participants
n=8 Participants
|
74 Participants
n=24 Participants
|
|
Race (NIH/OMB)
More than one race
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
3 Participants
n=24 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
5 Participants
n=24 Participants
|
|
Region of Enrollment
United States
|
5 participants
n=5 Participants
|
5 participants
n=7 Participants
|
9 participants
n=5 Participants
|
8 participants
n=4 Participants
|
9 participants
n=21 Participants
|
8 participants
n=8 Participants
|
45 participants
n=8 Participants
|
89 participants
n=24 Participants
|
PRIMARY outcome
Timeframe: 35 daysDefined as the dose level immediately below the dose level at which 2 patients of a cohort (of 2 to 6 patients) experience dose-limiting toxicity (DLT) or the maximum dose if less than or equal to 1 patient suffers a DLT at the maximum dose.
Outcome measures
| Measure |
Phase I
n=19 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Phase II (IL-2): 1.0 x 10^7/kg CIML NK Cells
The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
|
Phase I Dose Level 3: 1.0 x 10^7/kg CIML NK Cells
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Lead-in Cohort & Phase II (ALT-803): 1.0 x 10^7/kg CIML NK Cells
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0.
* Subcutaneous ALT-803 will begin approximately 4 hours after the infusion and will continue for a total of 2 doses (Days 0 and 5).
|
Phase II (IL-2): 1.0 x 10^7/kg CIML NK Cells
The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
|
Pediatric Cohort: 1.0 x 10^7/kg CIML NK Cells
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0
* Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses
|
|---|---|---|---|---|---|---|
|
Maximal Tolerated or Tested Dose (MT/TD) of CIML-NK Cells (Phase I)
|
1.0 x 10^7 cells/kg
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Up to 3 years* Complete remission rate (CR): Morphologically leukemia free state (i.e. bone marrow with \<5% blasts by morphologic criteria and no blasts with Auer rods, no evidence of extramedullary leukemia) and absolute neutrophil count ≥1000 /μL and platelets ≥100,000 /μL. Patient must be independent of transfusions * Complete Remission with Incomplete Blood Count Recovery (CRi): All of the above criteria for CR must be met, except that absolute neutrophils \<1000 /μL or platelets \<100,000 /μL in the blood.
Outcome measures
| Measure |
Phase I
n=8 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Phase II (IL-2): 1.0 x 10^7/kg CIML NK Cells
n=9 Participants
The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
|
Phase I Dose Level 3: 1.0 x 10^7/kg CIML NK Cells
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Lead-in Cohort & Phase II (ALT-803): 1.0 x 10^7/kg CIML NK Cells
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0.
* Subcutaneous ALT-803 will begin approximately 4 hours after the infusion and will continue for a total of 2 doses (Days 0 and 5).
|
Phase II (IL-2): 1.0 x 10^7/kg CIML NK Cells
The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
|
Pediatric Cohort: 1.0 x 10^7/kg CIML NK Cells
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0
* Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses
|
|---|---|---|---|---|---|---|
|
Complete Remission Rate (CR/CRi) in Participants With Relapsed or Refractory AML Following CIML NK Therapy (Phase II)
|
0 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Through Day 100* Graded using the National Cancer (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Related indicates possibly, probably, or definitely related to study treatment. * Adverse events will be collected from Day 0 to Day +35; however, bone marrow suppression (ANC \< 500/uL/µL) and AEs of GVHD involving the liver, skin, or GI tract will be recorded to Day 100.
Outcome measures
| Measure |
Phase I
n=8 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Phase II (IL-2): 1.0 x 10^7/kg CIML NK Cells
The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
|
Phase I Dose Level 3: 1.0 x 10^7/kg CIML NK Cells
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Lead-in Cohort & Phase II (ALT-803): 1.0 x 10^7/kg CIML NK Cells
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0.
* Subcutaneous ALT-803 will begin approximately 4 hours after the infusion and will continue for a total of 2 doses (Days 0 and 5).
|
Phase II (IL-2): 1.0 x 10^7/kg CIML NK Cells
The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
|
Pediatric Cohort: 1.0 x 10^7/kg CIML NK Cells
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0
* Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses
|
|---|---|---|---|---|---|---|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Chills : Grade 2
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Anorexia : Grade 2
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Anorexia : Grade 3
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Alanine aminotransferase increased : Grade 1
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Alanine aminotransferase increased : Grade 3
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Aspartate aminotransferase increased : Grade 1
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Aspartate aminotransferase increased : Grade 3
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Fever : Grade 3
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Hypertension : Grade 2
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Hyperammonemia : Grade 2
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Capillary leak syndrome : Grade 2
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Hypokalemia : Grade 1
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Hypophosphatemia : Grade 4
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Hypocalcemia: Grade 1
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Hypomagnesemia: Grade 1
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Hyperkalemia: Grade 1
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Headache: Grade 1
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Headache: Grade 2
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Myalgia: Grade 1
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Arthralgia: Grade 1
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Fatigue: Grade 1
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Injection site reaction: Grade 2
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Epistaxis: Grade 3
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Hematoma: Grade 1
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Paresthesia: Grade 1
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Pain: Grade 1
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Pain: Grade 2
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Sinus tachycardia: Grade 1
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Tachypnea: Grade 1
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Vomiting: Grade 1
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Skin induration: Grade 1
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Malaise: Grade 1
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Febrile neutropenia: Grade 1
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Flushing: Grade 1
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
Safety of CIML NK Cells as Measured by the Number of Participants With Treatment Related Adverse Events (Pediatric Cohort)
Hypoalbuminemia: Grade 1
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: 35 daysOutcome measures
| Measure |
Phase I
n=5 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Phase II (IL-2): 1.0 x 10^7/kg CIML NK Cells
n=5 Participants
The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
|
Phase I Dose Level 3: 1.0 x 10^7/kg CIML NK Cells
n=9 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Lead-in Cohort & Phase II (ALT-803): 1.0 x 10^7/kg CIML NK Cells
n=8 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0.
* Subcutaneous ALT-803 will begin approximately 4 hours after the infusion and will continue for a total of 2 doses (Days 0 and 5).
|
Phase II (IL-2): 1.0 x 10^7/kg CIML NK Cells
n=9 Participants
The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
|
Pediatric Cohort: 1.0 x 10^7/kg CIML NK Cells
n=8 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0
* Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses
|
|---|---|---|---|---|---|---|
|
Response Assessed According to IWG Criteria (Phase 1, Phase II, and Pediatric)
Progressive disease (PD)
|
1 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
4 Participants
|
|
Response Assessed According to IWG Criteria (Phase 1, Phase II, and Pediatric)
Complete remission (CR)
|
1 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Response Assessed According to IWG Criteria (Phase 1, Phase II, and Pediatric)
Complete remission with incomplete blood count recovery (CRi)
|
0 Participants
|
0 Participants
|
3 Participants
|
0 Participants
|
3 Participants
|
1 Participants
|
|
Response Assessed According to IWG Criteria (Phase 1, Phase II, and Pediatric)
Partial remission (PR)
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Response Assessed According to IWG Criteria (Phase 1, Phase II, and Pediatric)
Stable disease (SD)
|
0 Participants
|
1 Participants
|
0 Participants
|
6 Participants
|
1 Participants
|
2 Participants
|
|
Response Assessed According to IWG Criteria (Phase 1, Phase II, and Pediatric)
Treatment Failure (TF)
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
|
Response Assessed According to IWG Criteria (Phase 1, Phase II, and Pediatric)
Marrow complete response (mCR)
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Response Assessed According to IWG Criteria (Phase 1, Phase II, and Pediatric)
Morphologically leukemia-free state (MLFS)
|
0 Participants
|
1 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Response Assessed According to IWG Criteria (Phase 1, Phase II, and Pediatric)
Not evaluable
|
2 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: Up to 3 yearsPopulation: Only for patients who achieve a complete remission (CR), complete remission with incomplete blood count recovery (CRi), marrow complete response (mCR), or partial remission (PR).
DOR is defined only for patients who achieve a complete remission (CR), complete remission with incomplete blood count recovery (CRi), marrow complete response (mCR), or partial remission (PR), and is measured from the first date of attaining CR or PR until the date of disease progression or death.
Outcome measures
| Measure |
Phase I
n=1 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Phase II (IL-2): 1.0 x 10^7/kg CIML NK Cells
n=2 Participants
The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
|
Phase I Dose Level 3: 1.0 x 10^7/kg CIML NK Cells
n=4 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Lead-in Cohort & Phase II (ALT-803): 1.0 x 10^7/kg CIML NK Cells
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0.
* Subcutaneous ALT-803 will begin approximately 4 hours after the infusion and will continue for a total of 2 doses (Days 0 and 5).
|
Phase II (IL-2): 1.0 x 10^7/kg CIML NK Cells
n=3 Participants
The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
|
Pediatric Cohort: 1.0 x 10^7/kg CIML NK Cells
n=1 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0
* Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses
|
|---|---|---|---|---|---|---|
|
Duration of Remission (DOR) (Phase I, Phase II, and Pediatric)
|
126.0 days
Interval 126.0 to 126.0
|
22.0 days
Interval -29.0 to 73.0
|
76.5 days
Interval 21.0 to 208.0
|
—
|
30.0 days
Interval 6.0 to 35.0
|
80.0 days
Interval 80.0 to 80.0
|
SECONDARY outcome
Timeframe: Up to 3 yearsPopulation: Not evaluable: 2 patients Phase 1 Dose Level 1 (didn't receive adequate cell dose, expired before infusion). 2 patients Phase I Dose Level 2 (expired before infusion, received haplo transplant before PD). 3 patients Phase I Dose Level 3 (no bone marrow biopsy, 2-expired before PD). 2 patients Phase II IL-2 (2-no bone marrow biopsy). 1 patient Phase II ALT-803 (expired before response assessment). 2 patients Pediatric (expired before PD, poor bone marrow sample).
TTP is defined as the time from date of first dose of fludarabine until evidence of disease progression.
Outcome measures
| Measure |
Phase I
n=3 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Phase II (IL-2): 1.0 x 10^7/kg CIML NK Cells
n=3 Participants
The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
|
Phase I Dose Level 3: 1.0 x 10^7/kg CIML NK Cells
n=6 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Lead-in Cohort & Phase II (ALT-803): 1.0 x 10^7/kg CIML NK Cells
n=7 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0.
* Subcutaneous ALT-803 will begin approximately 4 hours after the infusion and will continue for a total of 2 doses (Days 0 and 5).
|
Phase II (IL-2): 1.0 x 10^7/kg CIML NK Cells
n=7 Participants
The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
|
Pediatric Cohort: 1.0 x 10^7/kg CIML NK Cells
n=6 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0
* Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses
|
|---|---|---|---|---|---|---|
|
Time to Progression (Phase I, Phase II, and Pediatric)
|
20.0 days
Interval 20.0 to 187.0
|
36.0 days
Interval 34.0 to 110.0
|
46.0 days
Interval 20.0 to 273.0
|
34.0 days
Interval 33.0 to 35.0
|
33.0 days
Interval 20.0 to 61.0
|
28.0 days
Interval 20.0 to 35.0
|
SECONDARY outcome
Timeframe: Up to 3 yearsPopulation: Only those patients with CR, mCR, or CRi are evaluable for this outcome measure.
DFS is defined as the time from the day CR, mCR, or CRi is documented until disease progression or death.
Outcome measures
| Measure |
Phase I
n=1 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Phase II (IL-2): 1.0 x 10^7/kg CIML NK Cells
n=2 Participants
The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
|
Phase I Dose Level 3: 1.0 x 10^7/kg CIML NK Cells
n=4 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Lead-in Cohort & Phase II (ALT-803): 1.0 x 10^7/kg CIML NK Cells
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0.
* Subcutaneous ALT-803 will begin approximately 4 hours after the infusion and will continue for a total of 2 doses (Days 0 and 5).
|
Phase II (IL-2): 1.0 x 10^7/kg CIML NK Cells
n=3 Participants
The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
|
Pediatric Cohort: 1.0 x 10^7/kg CIML NK Cells
n=1 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0
* Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses
|
|---|---|---|---|---|---|---|
|
Disease Free Survival (DFS) (Phase I, Phase II, and Pediatric)
|
126.00 days
|
73.00 days
Due to the small sample size (N=2), the 95% CI is not able to be estimated.
|
56.00 days
Interval 21.0 to 208.0
|
—
|
30.00 days
Interval 6.0 to 35.0
|
60.00 days
|
SECONDARY outcome
Timeframe: Up to 3 yearsOS is defined from the date of first dose of fludarabine on this study until death.
Outcome measures
| Measure |
Phase I
n=5 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Phase II (IL-2): 1.0 x 10^7/kg CIML NK Cells
n=5 Participants
The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
|
Phase I Dose Level 3: 1.0 x 10^7/kg CIML NK Cells
n=9 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Lead-in Cohort & Phase II (ALT-803): 1.0 x 10^7/kg CIML NK Cells
n=8 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0.
* Subcutaneous ALT-803 will begin approximately 4 hours after the infusion and will continue for a total of 2 doses (Days 0 and 5).
|
Phase II (IL-2): 1.0 x 10^7/kg CIML NK Cells
n=9 Participants
The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
|
Pediatric Cohort: 1.0 x 10^7/kg CIML NK Cells
n=8 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0
* Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses
|
|---|---|---|---|---|---|---|
|
Overall Survival (OS) (Phase I, Phase II, and Pediatric)
|
39.00 days
Interval 4.0 to 262.0
|
142.50 days
Interval 20.0 to 344.0
|
49.00 days
Interval 25.0 to 396.0
|
92.00 days
Interval 10.0 to 187.0
|
38.00 days
Interval 24.0 to 158.0
|
147.00 days
Interval 53.0 to 366.0
|
SECONDARY outcome
Timeframe: Through Day 100* Graded using the National Cancer (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Related indicates possibly, probably, or definitely related to study treatment. * AEs will be collected from Day 0 to Day +35; however, bone marrow suppression (ANC \< 500/uL/µL) and AEs of GVHD involving the liver, skin, or GI tract will be recorded to Day 100.
Outcome measures
| Measure |
Phase I
n=4 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Phase II (IL-2): 1.0 x 10^7/kg CIML NK Cells
n=5 Participants
The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
|
Phase I Dose Level 3: 1.0 x 10^7/kg CIML NK Cells
n=9 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Lead-in Cohort & Phase II (ALT-803): 1.0 x 10^7/kg CIML NK Cells
n=8 Participants
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0.
* Subcutaneous ALT-803 will begin approximately 4 hours after the infusion and will continue for a total of 2 doses (Days 0 and 5).
|
Phase II (IL-2): 1.0 x 10^7/kg CIML NK Cells
n=9 Participants
The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
|
Pediatric Cohort: 1.0 x 10^7/kg CIML NK Cells
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0
* Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses
|
|---|---|---|---|---|---|---|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Nausea: Grade 1
|
1 Participants
|
0 Participants
|
1 Participants
|
4 Participants
|
2 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Nausea: Grade 2
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Diarrhea: Grade 1
|
1 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Diarrhea: Grade 2
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Aspartate aminotransferase increased: Grade 1
|
1 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Alanine aminotransferase increased: Grade 1
|
2 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Proteinuria: Grade 1
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Proteinuria: Grade 2
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Blood bilirubin increased: Grade 1
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Blood bilirubin increased: Grade 2
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Alkaline phosphatase increased: Grade 1
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Sinus tachycardia: Grade 2
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Febrile neutropenia: Grade 3
|
1 Participants
|
0 Participants
|
0 Participants
|
6 Participants
|
6 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Malaise: Grade 1
|
1 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Malaise: Grade 2
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Rigors after IL-2 administration: Grade 2
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Hypoxia: Grade 2
|
0 Participants
|
0 Participants
|
1 Participants
|
3 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Dyspnea: Grade 2
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Confusion: Grade 2
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Confusion: Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Lethargy: Grade 2
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Chills: Grade 2
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
3 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Injection site reaction: Grade 1
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Injection site reaction: Grade 2
|
0 Participants
|
0 Participants
|
0 Participants
|
4 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Rigors after CIML NK cell infusion
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Alopecia: Grade 2
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Fatigue: Grade 1
|
0 Participants
|
0 Participants
|
0 Participants
|
5 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Fatigue: Grade 2
|
0 Participants
|
0 Participants
|
1 Participants
|
3 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Fatigue: Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Anorexia: Grade 1
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Anorexia: Grade 2
|
0 Participants
|
0 Participants
|
1 Participants
|
3 Participants
|
3 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Anorexia: Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Rigors: Grade 1
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Rigors: Grade 2
|
0 Participants
|
0 Participants
|
0 Participants
|
5 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Hypotension: Grade 1
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Hypotension: Grade 2
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Insomnia: Grade 2
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Encephalopathy: Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Wheezing: Grade 2
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Pulmonary edema: Grade 1
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Pulmonary edema: Grade 2
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Pleural effusion: Grade 2
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Cytokine release syndrome: Grade 1
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Cytokine release syndrome: Grade 2
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
2 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Capillary leak syndrome: Grade 2
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Fever: Grade 1
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Fever: Grade 2
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Vomiting: Grade 1
|
0 Participants
|
0 Participants
|
0 Participants
|
5 Participants
|
2 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Infusion related reaction: Grade 1
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Infusion related reaction: Grade 2
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Infusion related reaction: Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Hypertension: Grade 2
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Hypertension: Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
5 Participants
|
2 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Neutrophil count decreased: Grade 4
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Lymphocyte count decreased: Grade 4
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
White blood cell decreased: Grade 4
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Mucositis oral: Grade 1
|
0 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
2 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Mucositis oral: Grade 2
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Headache: Grade 1
|
0 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
1 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Headache: Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Sepsis: Grade 4
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Lung infection: Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
4 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Platelet count decreased: Grade 1
|
0 Participants
|
0 Participants
|
0 Participants
|
4 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Platelet count decreased: Grade 4
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Pulmonary alveolar hemorrhage: Grade 2
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Rash maculo-papular: Grade 1
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Abdominal pain: Grade 1
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Hyponatremia: Grade 1
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Hyponatremia: Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Hematuria: Grade 2
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Pruritus: Grade 1
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Creatinine increased: Grade 2
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Weight loss: Grade 1
|
0 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Bacteremia (strep mitis): Grade 3
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
|
Toxicity as Measured by the Number of Participants With Treatment Related Adverse Events (Phase I and Phase II)
Hypoalbuminemia: Grade 1
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
—
|
Adverse Events
Phase I Dose Level 1: 0.5 x 10^6/kg CIML NK Cells
Serious events: 2 serious events
Other events: 4 other events
Deaths: 5 deaths
Phase I Dose Level 2: 1.0 x 10^6/kg CIML NK Cells
Serious events: 0 serious events
Other events: 5 other events
Deaths: 4 deaths
Phase I Dose Level 3: Maximum NK Cell/Number kg
Serious events: 2 serious events
Other events: 9 other events
Deaths: 8 deaths
Lead-in Cohort & Phase II (ALT-803): Maximum NK Cell/Number kg
Serious events: 4 serious events
Other events: 8 other events
Deaths: 8 deaths
Phase II (IL-2): Maximum NK Cell/Number kg
Serious events: 4 serious events
Other events: 9 other events
Deaths: 9 deaths
Pediatric Cohort: Maximum NK Cell/Number kg
Serious events: 0 serious events
Other events: 8 other events
Deaths: 8 deaths
Donors
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Phase I Dose Level 1: 0.5 x 10^6/kg CIML NK Cells
n=4 participants at risk；n=5 participants at risk
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Phase I Dose Level 2: 1.0 x 10^6/kg CIML NK Cells
n=5 participants at risk
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Phase I Dose Level 3: Maximum NK Cell/Number kg
n=9 participants at risk
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Lead-in Cohort & Phase II (ALT-803): Maximum NK Cell/Number kg
n=8 participants at risk
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0.
* Subcutaneous ALT-803 will begin approximately 4 hours after the infusion and will continue for a total of 2 doses (Days 0 and 5).
|
Phase II (IL-2): Maximum NK Cell/Number kg
n=9 participants at risk
The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
|
Pediatric Cohort: Maximum NK Cell/Number kg
n=8 participants at risk
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0
* Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses
|
Donors
-The haploidentical donor identified by HLA matching of the immediate family members (parents, siblings, and children) will undergo non-mobilized leukapheresis on Day -1. Peripheral blood mononuclear cells (PBMCs) will be collected using standard collection techniques.
|
|---|---|---|---|---|---|---|---|
|
General disorders
Multi-organ failure
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Infections and infestations
Sepsis
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Metabolism and nutrition disorders
Hypokalemia
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Musculoskeletal and connective tissue disorders
Muscle weakness lower limb
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Death due to acute myeloid leukemia
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Nervous system disorders
Encephalopathy
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Respiratory, thoracic and mediastinal disorders
Cardiopulmonary arrest
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
Other adverse events
| Measure |
Phase I Dose Level 1: 0.5 x 10^6/kg CIML NK Cells
n=4 participants at risk；n=5 participants at risk
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Phase I Dose Level 2: 1.0 x 10^6/kg CIML NK Cells
n=5 participants at risk
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Phase I Dose Level 3: Maximum NK Cell/Number kg
n=9 participants at risk
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.
* Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)
|
Lead-in Cohort & Phase II (ALT-803): Maximum NK Cell/Number kg
n=8 participants at risk
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1.
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0.
* Subcutaneous ALT-803 will begin approximately 4 hours after the infusion and will continue for a total of 2 doses (Days 0 and 5).
|
Phase II (IL-2): Maximum NK Cell/Number kg
n=9 participants at risk
The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
|
Pediatric Cohort: Maximum NK Cell/Number kg
n=8 participants at risk
* Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.
* Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1
* CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0
* Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses
|
Donors
-The haploidentical donor identified by HLA matching of the immediate family members (parents, siblings, and children) will undergo non-mobilized leukapheresis on Day -1. Peripheral blood mononuclear cells (PBMCs) will be collected using standard collection techniques.
|
|---|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Anemia
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
50.0%
2/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
100.0%
5/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
66.7%
6/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
62.5%
5/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
77.8%
7/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Blood and lymphatic system disorders
Hemolysis
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Cardiac disorders
Atrial flutter
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Cardiac disorders
Heart failure
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Cardiac disorders
Left ventricular systolic dysfunction
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Cardiac disorders
NSTEMI
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Cardiac disorders
Right ventricular dysfunction
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Cardiac disorders
Sinus bradycardia
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Cardiac disorders
Sinus tachycardia
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
37.5%
3/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Cardiac disorders
Supraventricular tachycardia
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Ear and labyrinth disorders
Impacted cerumen
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Ear and labyrinth disorders
Tinnitus
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Eye disorders
Double vision
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Eye disorders
Ptosis
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Eye disorders
Retinal hemorrhage
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Gastrointestinal disorders
Abdominal pain
|
50.0%
2/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Gastrointestinal disorders
Anal ulcer
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Gastrointestinal disorders
Constipation
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Gastrointestinal disorders
Diarrhea
|
50.0%
2/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
50.0%
4/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
66.7%
6/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Gastrointestinal disorders
Dysphagia
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Gastrointestinal disorders
Epigastric pain
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Gastrointestinal disorders
Fecal incontinence
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Gastrointestinal disorders
Gastroesophageal reflux disease
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Gastrointestinal disorders
Hemorrhoids
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Gastrointestinal disorders
Ileus
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Gastrointestinal disorders
Lip pain
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Gastrointestinal disorders
Lower gastrointestinal hemorrhage
|
50.0%
2/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Gastrointestinal disorders
Mucositis oral
|
50.0%
2/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
40.0%
2/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
55.6%
5/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
75.0%
6/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
55.6%
5/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Gastrointestinal disorders
Nausea
|
50.0%
2/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
40.0%
2/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
44.4%
4/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
87.5%
7/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
44.4%
4/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Gastrointestinal disorders
Oral hemorrhage
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Gastrointestinal disorders
Oral pain
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Gastrointestinal disorders
Oral ulcer
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Gastrointestinal disorders
Proctitis
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Gastrointestinal disorders
Tongue ulceration
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Gastrointestinal disorders
Vomiting
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
75.0%
6/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
55.6%
5/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
General disorders
Axilla pain/swelling
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
General disorders
Body aches
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
General disorders
Burning at femoral area
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
General disorders
CVC site tender
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
General disorders
Chills
|
50.0%
2/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
40.0%
2/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
55.6%
5/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
44.4%
4/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
75.0%
6/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
General disorders
Diffuse body aches
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
General disorders
Edema face
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
General disorders
Edema limbs
|
50.0%
2/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
40.0%
2/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
55.6%
5/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
37.5%
3/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
General disorders
Fatigue
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
60.0%
3/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
75.0%
6/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
77.8%
7/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
General disorders
Fever
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
50.0%
4/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
General disorders
Gait disturbance
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
General disorders
Infusion related reaction
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
55.6%
5/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
General disorders
Injection site reaction
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
62.5%
5/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
General disorders
Irritability
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
General disorders
Localized edema
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
General disorders
Malaise
|
50.0%
2/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
General disorders
Pain
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
75.0%
6/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
General disorders
Rigors
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
44.4%
4/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
75.0%
6/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
General disorders
Rigors after IL-2 administration
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Hepatobiliary disorders
Gallstones
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Hepatobiliary disorders
Hyperammonemia
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Immune system disorders
Allergic reaction
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Immune system disorders
Cytokine release syndrome
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
37.5%
3/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
44.4%
4/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Infections and infestations
Angioinvasive fungus
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Infections and infestations
Bacteremia
|
50.0%
2/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Infections and infestations
Bacteremia-Rothia mucilaginosa
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Infections and infestations
Candidemia
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Infections and infestations
E. faecium in stool
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Infections and infestations
Folliculitis
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Infections and infestations
HHV-6
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Infections and infestations
Influenza AH3
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Infections and infestations
Lung infection
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
50.0%
4/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Infections and infestations
Oral thrush
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Infections and infestations
Paronychia
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Infections and infestations
Rhinitis infective
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Infections and infestations
Sepsis
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
40.0%
2/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Infections and infestations
Sinusitis
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Infections and infestations
Skin infection
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
40.0%
2/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Infections and infestations
Sphingomonas in blood
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Infections and infestations
VRE enterococcus species, stool bacteremia
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Infections and infestations
Vaginal infection
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Injury, poisoning and procedural complications
Bleeding from trifusion site
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Injury, poisoning and procedural complications
Bruising
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
44.4%
4/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Injury, poisoning and procedural complications
Fall
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Injury, poisoning and procedural complications
Foley catheter pain
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Injury, poisoning and procedural complications
Pain at bone marrow biopsy site
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Injury, poisoning and procedural complications
Scalp hematoma post fall
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Injury, poisoning and procedural complications
Subarachnoid hemorrhage post fall
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Injury, poisoning and procedural complications
Tenderness at bone marrow biopsy site
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Investigations
Activated partial thromboplastin time prolonged
|
50.0%
2/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Investigations
Alanine aminotransferase increased
|
75.0%
3/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
40.0%
2/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
44.4%
4/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
62.5%
5/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Investigations
Alkaline phosphatase increased
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
60.0%
3/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Investigations
Aspartate aminotransferase increased
|
50.0%
2/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
44.4%
4/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
50.0%
4/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
44.4%
4/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
37.5%
3/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Investigations
Blood bilirubin increased
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
37.5%
3/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Investigations
Cardiac troponin I increased
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Investigations
Creatinine increased
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Investigations
Electrocardiogram QT corrected interval prolonged
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Investigations
INR increased
|
50.0%
2/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
40.0%
2/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
55.6%
5/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Investigations
Lymphocyte count decreased
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Investigations
Neutrophil count decreased
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Investigations
Platelet count decreased
|
50.0%
2/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
40.0%
2/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Investigations
Weight gain
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Investigations
Weight loss
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
75.0%
6/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Investigations
White blood cell decreased
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Metabolism and nutrition disorders
Acidosis
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Metabolism and nutrition disorders
Alkalosis
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Metabolism and nutrition disorders
Anorexia
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
50.0%
4/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
77.8%
7/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Metabolism and nutrition disorders
Hyperglycemia
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Metabolism and nutrition disorders
Hyperkalemia
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Metabolism and nutrition disorders
Hypermagnesemia
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Metabolism and nutrition disorders
Hypernatremia
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
40.0%
2/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Metabolism and nutrition disorders
Hypertriglyceridemia
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Metabolism and nutrition disorders
Hyperuricemia
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Metabolism and nutrition disorders
Hypoalbuminemia
|
75.0%
3/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
40.0%
2/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
37.5%
3/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
62.5%
5/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Metabolism and nutrition disorders
Hypocalcemia
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
40.0%
2/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
37.5%
3/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
87.5%
7/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Metabolism and nutrition disorders
Hypoglycemia
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Metabolism and nutrition disorders
Hypokalemia
|
50.0%
2/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
40.0%
2/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
44.4%
4/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
75.0%
6/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
66.7%
6/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
37.5%
3/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Metabolism and nutrition disorders
Hypomagnesemia
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
50.0%
4/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
37.5%
3/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Metabolism and nutrition disorders
Hyponatremia
|
75.0%
3/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
44.4%
4/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
75.0%
6/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
62.5%
5/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Metabolism and nutrition disorders
Hypophosphatemia
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
40.0%
2/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
77.8%
7/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
62.5%
5/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
37.5%
3/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Renal and urinary disorders
Hematuria
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
40.0%
2/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
50.0%
4/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
44.4%
4/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Musculoskeletal and connective tissue disorders
Buttock pain
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Musculoskeletal and connective tissue disorders
Facial muscle weakness
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Musculoskeletal and connective tissue disorders
Generalized aches and pain
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Musculoskeletal and connective tissue disorders
Generalized muscle weakness
|
50.0%
2/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Musculoskeletal and connective tissue disorders
Muscle tension left side of head
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
37.5%
3/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Musculoskeletal and connective tissue disorders
Right posterior knee knot
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Musculoskeletal and connective tissue disorders
Tendonitis
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Disease progression of central nervous system
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neuroendocrine tumor
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Nervous system disorders
Decreased motor function
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Nervous system disorders
Depressed level of consciousness
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Nervous system disorders
Dysgeusia
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Nervous system disorders
Encephalopathy
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Nervous system disorders
Headache
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
37.5%
3/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
37.5%
3/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Renal and urinary disorders
Proteinuria
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
40.0%
2/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
87.5%
7/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
55.6%
5/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Nervous system disorders
Intracranial hemorrhage
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Nervous system disorders
Lethargy
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Nervous system disorders
Paresthesia
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Nervous system disorders
Sinus pain
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Nervous system disorders
Somnolence
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
44.4%
4/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Nervous system disorders
Stroke
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Nervous system disorders
Tremor
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Nervous system disorders
Worsening blepharospasm
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Psychiatric disorders
Confusion
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Psychiatric disorders
Delirium
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Psychiatric disorders
Insomnia
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Psychiatric disorders
Restlessness
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Renal and urinary disorders
Acute kidney injury
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Renal and urinary disorders
Burning with urination
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Renal and urinary disorders
Cystitis noninfective
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Renal and urinary disorders
Dysuria
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Renal and urinary disorders
Urinary frequency
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Renal and urinary disorders
Urinary incontinence
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Skin and subcutaneous tissue disorders
Purpura
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Renal and urinary disorders
Urinary urgency
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Reproductive system and breast disorders
Paraphimosis
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Reproductive system and breast disorders
Penile bloody discharge
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Reproductive system and breast disorders
Penile pain
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Respiratory, thoracic and mediastinal disorders
Aspiration
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Respiratory, thoracic and mediastinal disorders
Atelectasis
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
40.0%
2/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
37.5%
3/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
37.5%
3/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Respiratory, thoracic and mediastinal disorders
Hoarseness
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
55.6%
5/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
37.5%
3/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
44.4%
4/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Respiratory, thoracic and mediastinal disorders
Pleuritic pain
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Respiratory, thoracic and mediastinal disorders
Possible aspiration
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary alveolar hemorrhage/DAH
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary edema
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
44.4%
4/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary nodule
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Respiratory, thoracic and mediastinal disorders
Tachypnea-intermittent
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Skin and subcutaneous tissue disorders
Abrasion
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Skin and subcutaneous tissue disorders
Blister of left great toe
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Skin and subcutaneous tissue disorders
Ecchymosis
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
37.5%
3/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Skin and subcutaneous tissue disorders
Erythema around central line
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Skin and subcutaneous tissue disorders
Leukemia cutis
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Skin and subcutaneous tissue disorders
Night sweats
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Skin and subcutaneous tissue disorders
Periorbital edema
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Skin and subcutaneous tissue disorders
Petechiae
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Skin and subcutaneous tissue disorders
Skin breakdown
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Skin and subcutaneous tissue disorders
Skin hyperpigmentation
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Skin and subcutaneous tissue disorders
Skin induration
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Skin and subcutaneous tissue disorders
Skin lesions
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Skin and subcutaneous tissue disorders
Skin ulceration
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Vascular disorders
Capillary leak syndrome
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Vascular disorders
Flushing
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Vascular disorders
Hematoma
|
25.0%
1/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Vascular disorders
Hypertension
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
20.0%
1/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
22.2%
2/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
75.0%
6/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
66.7%
6/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
37.5%
3/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Vascular disorders
Hypotension
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
60.0%
3/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
33.3%
3/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
25.0%
2/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
66.7%
6/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
37.5%
3/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Vascular disorders
Lymphedema
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Vascular disorders
Subdural hematoma
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Vascular disorders
Superficial thrombophlebitis
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
|
Vascular disorders
Thromboembolic event
|
0.00%
0/4 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/5 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
12.5%
1/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
11.1%
1/9 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
0.00%
0/8 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
—
0/0 • -Adverse events were collected from Day 0 to Day +35; however, bone marrow suppression (ANC < 500/uL/µL) and adverse events of GVHD involving the liver, skin, or GI tract will be recorded to Day 100. -Phase I Dose Level 1: One subject expired prior to CIML NK cell infusion and no adverse events were collected per protocol.
-Adverse events \& all-cause mortality were not collected for donors. All-cause mortality for all others were collected through completion of follow-up.
|
Additional Information
Amanda Cashen, M.D.
Washington University School of Medicine
Phone: 314-434-8323
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place